Mounjaro (tirzepatide) in India: a complete guide

What is Mounjaro, and how does it differ from pure GLP-1 drugs?

Mounjaro is the brand name for the drug tirzepatide. It is given as a Mounjaro injection under the skin once a week, and it belongs to a newer generation of metabolic medicines that build on the biology of gut hormones called incretins.

What makes tirzepatide stand out is that it is a “dual” medicine. The US FDA described it, at approval, as a first-in-class medicine that activates both the GLP-1 and the GIP receptor — the first single molecule to do so.^[2] Most of the other well-known medicines in this space, such as semaglutide, act on only one of those two receptors: the GLP-1 receptor. If you want the underlying science, our explainer on what GLP-1 is walks through how these receptors work, and our guide to semaglutide covers the best-known single-receptor drug.

That difference is not just marketing. The American Diabetes Association classifies tirzepatide as a “dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist” and states that, of the currently available agents, tirzepatide and semaglutide have the highest efficacy for both glucose lowering and weight loss, followed by dulaglutide, liraglutide and extended-release exenatide.^[7]

In plain terms: tirzepatide is one molecule doing two jobs, and independent guideline bodies place it at the top tier of the current options. That does not make it right for everyone — only a doctor can judge that — but it explains why it has drawn so much attention.

Mounjaro in India: approval, launch and forms available

Mounjaro reached India in 2025. Eli Lilly launched it on 21 March 2025 as a once-weekly injection approved by India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), reaching the market ahead of its main rival.^[1]

It arrived first as single-dose vials. Later, the multi-dose Mounjaro KwikPen— a prefilled, single-patient once-weekly pen — was introduced in India across six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, giving doctors more flexibility to titrate the dose.^[8] Press reporting indicates the KwikPen received CDSCO clearance around June 2025; that specific timing comes from secondary press coverage rather than a primary regulatory document, so treat it as approximate.^[9]

Why does India matter so much for a medicine like this? Because the country carries one of the world's heaviest metabolic-disease burdens. The IDF Diabetes Atlas (11th edition) estimated that India had 89.8 million adults aged 20–79 living with diabetes in 2024 — second only to China — with roughly 43% (about 38.6 million) still undiagnosed.^[10]

Tirzepatide is approved in India for both type 2 diabetes and weight management. The Endocrine Society of India's 2025 obesity guidelines note that tirzepatide (a GIP/GLP-1 dual agonist) is available in the Indian market and approved for weight loss in India.^[11][1]On the obesity side, the ICMR-INDIAB national study estimated 254 million Indian adults with generalised obesity (28.6%) and 351 million with abdominal obesity (39.5%), using Asian-Indian cut-offs of BMI at or above 25 kg/m² and a waist circumference of 90 cm or more in men and 80 cm or more in women.^[12]

The scale is global too. The World Health Organization reported that in 2022 about 2.5 billion adults were overweight, of whom 890 million were living with obesity — a recognised risk factor for type 2 diabetes and cardiovascular disease.^[13] For a broader view of the injectable medicines used in this area and how doctor-led programs approach them, see our overview of weight loss injections in India.

One important note on this page: because Mounjaro is a prescription-only medicine, we do not list prices or any way to buy it. Availability of a medicine is not the same as it being suitable for you — that judgment belongs to a consulting doctor.

How does Mounjaro work?

Tirzepatide works by drawing on the biology of incretins — hormones your gut releases after you eat. Two of these, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), help the pancreas release insulin when blood sugar rises. Most medicines in this class mimic just GLP-1.

Tirzepatide is different because it engages both pathways. It is, in the words of the trial investigators, a “dual GIP and GLP-1 receptor agonist” — a single engineered molecule that activates both receptors at once.^[5][2] The US FDA approved it as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes, which reflects how it is meant to be used: alongside lifestyle change, not instead of it.^[2]

The practical consequences of that dual action — on blood sugar and on body weight — are best understood through the clinical trials rather than through theory, so that is where we turn next. What the mechanism does not do is make tirzepatide a do-it-yourself medicine: the same biology that drives its effects is why it needs careful, supervised dosing.

What did clinical trials of tirzepatide find?

Tirzepatide was tested in two large trial programs: SURPASS, in people with type 2 diabetes, and SURMOUNT, in people with obesity or overweight. The numbers below are reported directly from those studies. They describe what happened to trial participants under study conditions — they are not a prediction of what will happen to any individual, and they are not an endorsement of the medicine for you.

How is Mounjaro dosed and administered?

Mounjaro is designed to be increased slowly, and the schedule below is taken directly from the FDA prescribing information. It is included here for understanding only — the actual dose, timing and any changes are decided and monitored by your prescribing doctor.

The label lists strengths of 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, and the medicine is given as a once-weekly subcutaneous injection.^[6]The 2.5 mg starting dose is a “lead-in” step to help the body adjust; it is not intended as a maintenance dose. The gradual titration exists precisely to reduce gastrointestinal side effects, which is one reason self-adjusting the dose is unsafe.

Storage matters with any injectable: the label advises keeping Mounjaro refrigerated at 2 to 8 °C (36 to 46 °F).^[6] If a doctor prescribes it, they and the pharmacist will explain injection technique, injection sites and storage in detail.

Side effects and who should not take it

No effective medicine is free of risk, and tirzepatide is no exception. The most frequently reported adverse reactions are gastrointestinal. At the 15 mg dose, the FDA label reports nausea in about 18% of patients, diarrhoea in 17%, decreased appetite in 11%, vomiting in 9% and constipation in 7%.^[6] These tend to be most noticeable when the dose is increased, which is part of why titration is slow and supervised.

Tirzepatide also carries a boxed warning— the most serious kind on a US label. In studies, tirzepatide caused thyroid C-cell tumours in rats; whether it does so in humans is not known. Because of this, the medicine is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC), and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^[6]

This is exactly the kind of detail that has to be screened for before a prescription. Your medical and family history, other conditions, other medicines and personal circumstances all feed into whether tirzepatide is appropriate — and that assessment can only be done by a registered doctor, not by a website or a questionnaire. If any warning sign appears while on treatment, the right step is to contact the prescribing doctor promptly.

A note on spelling: moun jaro, manjaro and what Mounjaro is not

The medicine is a lot easier to research once you know the right words for it. People searching for it often type variants such as “moun jaro” (with a space) or the “manjaro drug” misspelling. The correct brand name is Mounjaro, and its generic (non-proprietary) name is tirzepatide.

A couple of clarifications save confusion. Manjaro is also the name of an unrelated Linux computer operating system, and Kilimanjarois a mountain in Africa — neither has any connection to the medicine. If you have landed here after typing one of those variants, the Mounjaro discussed on this page is the once-weekly GIP/GLP-1 injection (tirzepatide) approved for type 2 diabetes and weight management.

Why a prescription and medical supervision are mandatory

Everything above points to one conclusion: Mounjaro is a serious, prescription-only medicine, not a lifestyle product. It is approved by regulators for specific medical uses, it carries a boxed warning and firm contraindications, it needs careful dose titration, and it can cause meaningful side effects.^[6]Those are not reasons to fear it — they are reasons it belongs in the hands of a doctor.

In India, Mounjaro is prescription-only and cannot be bought over the counter. That is by design. A registered medical practitioner needs to review your health history, screen for the contraindications, decide whether tirzepatide is appropriate at all, choose a starting plan, and monitor how you respond over time. If a doctor decides it is not suitable — or that further testing is needed first — that judgment stands.

This is also why MensMD never sells prescription medicines directly and never frames any drug as a guaranteed answer. The evidence from SURPASS and SURMOUNT is genuinely impressive, but a trial average is not a personal prescription. If you are exploring your options, the sensible path is a proper assessment and a conversation with a licensed doctor — which is how our weight-loss program is structured, with medical supervision built in rather than bolted on.

Frequently asked questions